CELLULAR THERAPY
CAR-T access for selected blood cancers.
Multiple myeloma, B-cell lymphomas and selected hematologic malignancies. Not all diseases or all patients qualify; suitability is determined through diagnosis-specific clinical review.
Clinical context
Multiple myeloma
B-cell lymphomas
Selected hematologic malignancies
Information typically needed
Diagnosis, pathology, prior systemic therapy, imaging and current disease status.
Treatment-center review
The relevant treating center determines eligibility and treatment planning based on the submitted clinical case.
International treatment considerations
Scope, timing and practical treatment arrangements are clarified before movement, once a route is identified.